Melissa G Lechner1, Angeli C Bernardo2,3, Alyssa Lampe4, Stephanie Smooke Praw1, Samantha H Tam5, Trevor E Angell4. 1. Division of Endocrinology, Diabetes, and Metabolism, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA. 2. Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. 3. Southern California Clinical and Translational Science Institute, Los Angeles, California, USA. 4. Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. 5. Department of Otolaryngology, Henry Ford Health System, Detroit, Michigan, USA.
Abstract
BACKGROUND: Recent revision significantly changed the American Joint Committee on Cancer (AJCC) staging criteria for differentiated thyroid cancer (DTC). To quantitatively evaluate resulting changes in patient stage distribution and the associated disease-specific survival (DSS) incorporating diverse populations, we performed a meta-analysis of studies comparing the AJCC 7th edition (AJCC-7) with 8th edition (AJCC-8) staging for DTC. MATERIALS AND METHODS: After PROSPERO registration (#CRD42019123657), publications in English reporting DSS of DTC with AJCC-7 and AJCC-8 from inception to June 2019 were identified by search of MEDLINE and PubMed. Random-effects meta-analyses were conducted to compare differences in survival between AJCC-7 and AJCC-8. Pooled hazard ratios, 10-year DSS, and corresponding interval estimates were calculated for AJCC subgroups. Differences in survival between editions were assessed using subgroup analysis with nonoverlapping confidence intervals indicating statistical significance. RESULTS: Final analysis included six studies with 10,850 subjects and median follow-up from 55 to 148 months. Use of AJCC-8 shifted classification to earlier stages: stage I, from 60% to 81%; stage II, from 5% to 13%; stage III, from 21% to 2%; stage IV, from 10% to 3%. Ten-year DSS was significantly lower in AJCC-8 versus AJCC-7 in patients with stage II (88.6%, 95% confidence interval [CI] 82.7-94.6% vs. 98.1%, 95% CI 96.6-99.6%, respectively) and stage III disease (70.5%, 95% CI 59.1-83.9% vs. 96.8%, 95% CI 94.1-99.64%, respectively). CONCLUSION: Meta-analysis of revised AJCC staging for DTC, incorporating diverse populations, demonstrates redistribution of patients toward earlier clinical stages and better stratification of disease-specific mortality risk, specifically among patients now classified with stage II and III disease. IMPLICATIONS FOR PRACTICE: This study provides updated estimates of disease-specific survival for patients with differentiated thyroid cancer determined by the American Joint Committee on Cancer staging system that are generalizable to broader populations and support improved stratification using the recently revised criteria.
BACKGROUND: Recent revision significantly changed the American Joint Committee on Cancer (AJCC) staging criteria for differentiated thyroid cancer (DTC). To quantitatively evaluate resulting changes in patient stage distribution and the associated disease-specific survival (DSS) incorporating diverse populations, we performed a meta-analysis of studies comparing the AJCC 7th edition (AJCC-7) with 8th edition (AJCC-8) staging for DTC. MATERIALS AND METHODS: After PROSPERO registration (#CRD42019123657), publications in English reporting DSS of DTC with AJCC-7 and AJCC-8 from inception to June 2019 were identified by search of MEDLINE and PubMed. Random-effects meta-analyses were conducted to compare differences in survival between AJCC-7 and AJCC-8. Pooled hazard ratios, 10-year DSS, and corresponding interval estimates were calculated for AJCC subgroups. Differences in survival between editions were assessed using subgroup analysis with nonoverlapping confidence intervals indicating statistical significance. RESULTS: Final analysis included six studies with 10,850 subjects and median follow-up from 55 to 148 months. Use of AJCC-8 shifted classification to earlier stages: stage I, from 60% to 81%; stage II, from 5% to 13%; stage III, from 21% to 2%; stage IV, from 10% to 3%. Ten-year DSS was significantly lower in AJCC-8 versus AJCC-7 in patients with stage II (88.6%, 95% confidence interval [CI] 82.7-94.6% vs. 98.1%, 95% CI 96.6-99.6%, respectively) and stage III disease (70.5%, 95% CI 59.1-83.9% vs. 96.8%, 95% CI 94.1-99.64%, respectively). CONCLUSION: Meta-analysis of revised AJCC staging for DTC, incorporating diverse populations, demonstrates redistribution of patients toward earlier clinical stages and better stratification of disease-specific mortality risk, specifically among patients now classified with stage II and III disease. IMPLICATIONS FOR PRACTICE: This study provides updated estimates of disease-specific survival for patients with differentiated thyroid cancer determined by the American Joint Committee on Cancer staging system that are generalizable to broader populations and support improved stratification using the recently revised criteria.
Authors: Lindsay A Bischoff; Joseph Curry; Intekhab Ahmed; Edmund Pribitkin; Jeffrey L Miller Journal: Endocr Pract Date: 2013 Nov-Dec Impact factor: 3.443
Authors: Tae Hyuk Kim; Young Nam Kim; Hye In Kim; So Young Park; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Young Lyun Oh; Soo Yeon Hahn; Jung Hee Shin; Kyunga Kim; Jong Gill Jeong; Sun Wook Kim; Jae Hoon Chung Journal: Oral Oncol Date: 2017-06-10 Impact factor: 5.337
Authors: Samantha Tam; Mongkol Boonsripitayanon; Moran Amit; Bryan M Fellman; Yisheng Li; Naifa L Busaidy; Maria E Cabanillas; Ramona Dadu; Steve Sherman; Steven G Waguespack; Michelle D Williams; Ryan P Goepfert; Neil D Gross; Nancy D Perrier; Erich M Sturgis; Mark E Zafereo Journal: Thyroid Date: 2018-10 Impact factor: 6.568
Authors: Lauren N Pontius; Taofik O Oyekunle; Samantha M Thomas; Michael T Stang; Randall P Scheri; Sanziana A Roman; Julie A Sosa Journal: Thyroid Date: 2017-10-05 Impact factor: 6.568